Tag: Clinical Pharmacology Award

Vibhu Sahani | Pharmacology | Lifetime Achievement Award

Published on by World Science Awards

Lifetime Achievement Award

Vibhu Sahani
LLRM Medical College, Meerut
Vibhu Sahani
Affiliation LLRM Medical College, Meerut
Country India
Scopus ID 59031594100
Documents 7
Citations 8
h-index 1
Subject Area Pharmacology
Event World Science Awards

The Lifetime Achievement Award recognizes sustained academic service, scholarly engagement, and professional contributions within a scientific discipline. Vibhu Sahani of LLRM Medical College, Meerut has contributed to the field of pharmacology through research, scholarly publication, and academic activities. The available bibliometric information indicates participation in peer-reviewed scientific communication and ongoing involvement in pharmacological research.[1]

Abstract

Vibhu Sahani is an academic associated with LLRM Medical College, Meerut, India, whose scholarly work is focused on pharmacology. His published research contributes to the understanding of pharmacological science and supports continued advancement in medical research. Available bibliometric indicators, including indexed publications and citations, reflect participation in the international scientific literature and ongoing academic engagement.[1][2]

Keywords

  • Pharmacology
  • Drug Research
  • Medical Science
  • Clinical Pharmacology
  • Biomedical Research
  • Scientific Publications
  • Research Impact
  • World Science Awards

Introduction

Pharmacology is a multidisciplinary scientific field dedicated to understanding the mechanisms, therapeutic applications, efficacy, and safety of medicinal compounds. Research in pharmacology contributes significantly to disease prevention, treatment innovation, and evidence-based healthcare. Academic researchers working in this discipline support advances through laboratory investigations, clinical studies, and scientific publication.[3]

Research Profile

Based on the available Scopus data, Vibhu Sahani has authored seven indexed documents, received eight citations, and holds an h-index of one. These bibliometric indicators demonstrate participation in scholarly research and publication within pharmacology while contributing to the scientific literature through peer-reviewed academic work.[1]

  • Affiliation with LLRM Medical College, Meerut.
  • Primary research area: Pharmacology.
  • Indexed scientific publications: 7.
  • Total citations: 8.
  • Scopus h-index: 1.

Research Contributions

The available publication record indicates contributions to pharmacological investigations and medical science. Research activities in this field support the understanding of therapeutic interventions, drug action, patient care, and evidence-based medicine. Such scholarly contributions form an important part of continued scientific development in healthcare disciplines.[2][3]

Publications

The researcher’s publication portfolio includes peer-reviewed scientific articles indexed within international scholarly databases. These publications demonstrate participation in academic research and dissemination of scientific findings relevant to pharmacology and associated biomedical disciplines.[1]

  • Peer-reviewed journal publications.
  • Pharmacological and biomedical research.
  • Scientific collaboration and academic dissemination.
  • Indexed scholarly contributions.

Research Impact

Research impact is commonly evaluated through publication output, citation performance, scholarly visibility, and contribution to scientific knowledge. The available metrics indicate that Vibhu Sahani has established an indexed research presence in pharmacology. These bibliometric indicators provide objective evidence of participation in scholarly communication while supporting continued academic development.[1]

Award Suitability

Based on the information provided, Vibhu Sahani demonstrates academic engagement through research publication, institutional affiliation, and contributions to pharmacology. Consideration for recognition within the World Science Awards may acknowledge sustained scholarly participation and professional service. Final award decisions should be based on the complete evaluation criteria established by the organizing committee, including academic achievements, research quality, professional experience, and broader scientific contributions.[1][2]

Conclusion

Vibhu Sahani has contributed to pharmacological research through scholarly publication and academic engagement at LLRM Medical College, Meerut. His indexed research record reflects participation in scientific communication and supports ongoing advancement within the biomedical sciences. The documented academic profile provides an objective overview of research activity relevant to professional recognition in the scientific community.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Vibhu Sahani, Author ID 59031594100. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59031594100
  2. World Science Awards. (n.d.). Recognition of scientific excellence through international academic awards.
    https://worldscienceawards.com/
  3. Goodman & Gilman’s. The Pharmacological Basis of Therapeutics.
  4. Nature Reviews Drug Discovery. Drug discovery and pharmacological innovation.
    DOI: https://doi.org/10.1038/nrd.2017.232

Ved Pal | Pharmacology | Innovative Research Award

Published on by World Science Awards

Innovative Research Award

Ved Pal
Affiliation ISF College of Pharmacy, Moga, Punjab
Country India
Scopus ID 59895257200
Documents 3
Citations 5
h-index 1
Subject Area Pharmacology
Event World Science Awards
ORCID 0000-0003-3523-1469

Ved Pal
ISF College of Pharmacy, Moga, Punjab, India

The Innovative Research Award recognizes researchers whose scholarly activities demonstrate sustained commitment to scientific advancement, innovation, and academic excellence. VED PAL, affiliated with ISF College of Pharmacy, Moga, Punjab, has established an academic profile in the field of pharmacology through research contributions, professional engagement, and participation in internationally recognized scholarly platforms.[1]

Abstract

VED PAL is an academic researcher associated with ISF College of Pharmacy, Moga, Punjab, India. His scholarly interests are centered on pharmacology, an interdisciplinary field that integrates pharmaceutical sciences, biomedical research, and therapeutic innovation. His academic profile reflects ongoing engagement with scientific publication, research dissemination, and professional development within the pharmaceutical sciences.[1][2]

Keywords

Pharmacology, Pharmaceutical Sciences, Drug Research, Biomedical Science, Therapeutics, Academic Research, Scientific Publications, Innovation, World Science Awards, Healthcare Research.

Introduction

Pharmacology remains one of the most significant scientific disciplines supporting healthcare innovation through the study of medicines, therapeutic mechanisms, and biological responses. Researchers working in this field contribute toward improving evidence-based healthcare, advancing pharmaceutical technologies, and supporting interdisciplinary scientific collaboration. Academic recognition programs acknowledge these contributions by evaluating research quality, scholarly productivity, and scientific impact using internationally recognized academic indicators.[2][3]

Research Profile

VED PAL is affiliated with ISF College of Pharmacy in Punjab, India, where his academic interests align with pharmacological research and pharmaceutical sciences. His scholarly identity is represented through internationally recognized researcher identifiers, including a Scopus Author ID and an ORCID profile, supporting transparency in research attribution and academic visibility.[1][4]

Research Contributions

Research activities in pharmacology typically involve investigations related to drug discovery, therapeutic evaluation, pharmacodynamics, pharmacokinetics, toxicology, and clinical relevance. Through academic participation and publication activities, VED PAL contributes to the broader scientific dialogue supporting pharmaceutical research and evidence-driven healthcare. Such contributions encourage collaboration between academic institutions and the scientific community while promoting responsible research practices.[2][5]

Publications

The researcher’s scholarly output is indexed through the Scopus author profile associated with Author ID 59895257200. Publication records, citation data, and bibliographic information are maintained through recognized academic indexing systems, allowing researchers and institutions to monitor scientific productivity and collaboration.[1]

Research Impact

Research impact extends beyond publication volume and includes scientific influence, collaboration, knowledge dissemination, and practical application of research findings. International researcher identifiers such as ORCID and Scopus improve research discoverability, strengthen scholarly communication, and facilitate accurate attribution across academic databases. These systems support transparent evaluation of academic achievements within the global research ecosystem.[1][4]

Award Suitability

The Innovative Research Award recognizes researchers demonstrating commitment to scholarly excellence, ethical research practices, scientific innovation, and meaningful contributions within their discipline. Based on the available academic identifiers, institutional affiliation, and specialization in pharmacology, VED PAL represents a researcher whose profile aligns with the objectives of recognizing ongoing scientific engagement and academic development through the World Science Awards.[5]

Conclusion

VED PAL’s academic profile reflects continued participation in pharmaceutical research and international scholarly communication. Through institutional affiliation, recognized researcher identifiers, and engagement with pharmacological sciences, the profile illustrates a commitment to research integrity, scientific advancement, and professional development. Recognition through the Innovative Research Award highlights the importance of sustained contributions to contemporary scientific research while encouraging future innovation within the pharmaceutical sciences.[1][5]

References

  1. Elsevier. (n.d.). Scopus Author Details: VED PAL, Author ID 59895257200. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59895257200
  2. Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2023). Goodman & Gilman’s The Pharmacological Basis of Therapeutics.
    DOI: https://doi.org/10.1038/s41573-021-00234-4
  3. World Health Organization. (n.d.). Research for Health.
    https://www.who.int
  4. ORCID. (n.d.). ORCID Record: 0000-0003-3523-1469.
    https://orcid.org/0000-0003-3523-1469
  5. World Science Awards. (n.d.). Award Evaluation and Recognition Framework.
    https://worldscienceawards.com/

Liang Zhou | Clinical Pharmacology | Best Researcher Award

Published on by World Science Awards

Ms. Liang Zhou | Clinical Pharmacology | Best Researcher Award

Shanghai Henlius Biotech Inc., China

Ms. Liang Zhou is a distinguished clinical pharmacology professional with extensive experience in oncology drug development, pharmacokinetics, and translational research. She earned her Master’s degree in Drug Metabolism and Pharmacokinetics from the China Pharmaceutical University in 2008, which laid the foundation for her successful career in pharmaceutical sciences. Over the years, she has held progressive positions in leading global and Chinese organizations, including Associate Senior Scientist at Wuxi Apptec, Demo Chemist at Thermo Fisher Shanghai, Associate Director of Clinical Pharmacology at Mosim, and currently serves as the Senior Director of Clinical Pharmacology at Shanghai Henlius Biotech, Inc. since 2021. In these roles, she has contributed to more than 11 significant clinical trial programs across China, Australia, Japan, Europe, and the United States, with a strong focus on first-in-human (FIH) trials, PK/PD analysis, and oncology indications such as breast cancer, lymphoma, AML, NSCLC, gastric and pancreatic cancers, among others. Her research interests center on oncology drug development, dose exploration studies, biomarker integration, and regulatory science to accelerate access to novel therapies. With 23 academic documents, 91 citations, and an h-index of 4, Ms. Zhou demonstrates measurable scholarly impact, supported by her memberships in professional societies such as the Chinese Society of Clinical Oncology (CSCO). She has also enhanced her expertise through specialized training in GCP compliance, oncology drug development, and advanced pharmacometrics including R-language applications. Her skills encompass pharmacokinetic modeling, clinical trial design, regulatory submission, and team leadership, which collectively position her as a key figure in clinical pharmacology. Recognized for her contributions to cancer research and drug development, she continues to build a strong professional profile with the potential for international recognition. In conclusion, Ms. Liang Zhou’s blend of academic excellence, clinical research leadership, and commitment to advancing oncology therapeutics makes her a deserving candidate for prestigious awards and a driving force in global biomedical innovation.

Profile: Scopus

Featured Publications

Li, X., Zhang, Y., Wang, J., Chen, H., Zhou, L., Liu, M., … [et al.]. (2023). HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: An open-label, dose-escalation, phase 1 trial.(5)

Asif Khaliq | Pharmaceutical Sciences | Best Researcher Award

Published on by World Science Awards

Dr. Asif Khaliq | Pharmaceutical Sciences | Best Researcher Award

Dr. Asif Khaliq is a distinguished clinical pharmacist and public health researcher with extensive experience across Pakistan and Australia. With over 15 years of cumulative expertise in pharmacy practice, healthcare management, and academic research, he has played pivotal roles in both hospital settings and global health research initiatives. Dr. Khaliq currently serves as a Clinical Pharmacist at Atherton Hospital, Queensland Health, where he contributes to medication reconciliation, patient consultation, and therapeutic drug monitoring. His broad qualifications in pharmacy, public health, and health management uniquely position him at the intersection of clinical service and evidence-based research. Notably, he has authored around 30 peer-reviewed journal articles and has presented his work at several international conferences. His commitment to improving patient care is reflected in his involvement in projects on antimicrobial stewardship, immunization safety, medication cost optimization, and community health surveillance. A registered pharmacist in both Australia and Pakistan, Dr. Khaliq continues to expand his professional credentials through ongoing training and professional development. His multidisciplinary knowledge and dedication to collaborative, data-driven healthcare improvement make him a leading candidate for honors in research and clinical excellence.

Professional Profile

Education

Dr. Asif Khaliq possesses a diverse and robust academic background that integrates pharmacy, health management, and public health. He earned his Doctor of Pharmacy (PharmD) from the University of Karachi in 2009, laying a solid foundation in pharmaceutical sciences. He later pursued an MBA in Health Management from the Institute of Business Management (IoBM), Karachi, in 2014, equipping him with managerial and strategic skills essential for healthcare administration. In 2017, he obtained a Master of Public Health (MPH) from Baqai Medical University, further expanding his expertise into population health, disease prevention, and health systems. Most recently, he completed a Ph.D. in Public Health at Queensland University of Technology (QUT), Australia, in 2023. His doctoral research focused on critical issues in public health, integrating practical clinical knowledge with research methodologies. In addition to these core degrees, Dr. Khaliq has cleared the Knowledge Assessment of Pharmaceutical Sciences (KAPS) by the Australian Pharmacy Council and has demonstrated English language proficiency through PTE Academic. His academic trajectory reflects a commitment to lifelong learning and interdisciplinary mastery, qualifying him to address complex healthcare challenges at both clinical and systemic levels.

Professional Experience

Dr. Khaliq’s professional journey spans multiple sectors, including hospital pharmacy, public health research, and academic instruction. Currently, he serves as a Clinical Pharmacist at Atherton Hospital under Queensland Health, where he provides vital services including medication review, drug interaction management, therapeutic optimization, and discharge planning. His responsibilities also involve daily clinical monitoring and interdisciplinary collaboration with physicians and nursing staff. Previously, he held pharmacist roles at Infinity Pharmacy Earlville Upper, Allora Pharmacy, and Boulder Pharmacy across Queensland, Australia. In these roles, he handled immunization services, controlled substance management, MedsChecks, and patient counseling. Notably, Dr. Khaliq served as a Research Coordinator at Aga Khan University Hospital, Pakistan, where he supervised international clinical trials and led efforts in typhoid outbreak investigations. He also worked in various pharmacist roles at Aga Khan University Hospital’s emergency and pediatrics departments, gaining critical experience in medication reconciliation, IV-to-oral drug conversions, and poison management. His early career included logistics and inventory roles with Médecins Sans Frontières, further enriching his understanding of pharmaceutical supply chains. This comprehensive experience makes Dr. Khaliq uniquely capable of blending clinical insights with research acumen and operational excellence.

Research Interests

Dr. Asif Khaliq’s research interests lie at the nexus of clinical pharmacy, public health, and healthcare systems management. He is particularly focused on areas such as antimicrobial stewardship, vaccine safety and immunogenicity, medication adherence, and cost-effective therapeutic strategies. During his Ph.D. studies at Queensland University of Technology, he explored healthcare outcomes linked to pharmacological practices and population-level health interventions. His work frequently integrates health surveillance, epidemiology, and evidence-based medicine to address real-world challenges in both hospital and community settings. He has led or contributed to major research projects including randomized controlled trials on antibiotic use in pediatric diarrhea and typhoid outbreak control. In recent roles, he has also investigated adverse events following immunization (AEFI), resistance patterns in Salmonella species, and systematic reviews on outbreak trends in developing regions. Dr. Khaliq is deeply committed to identifying research gaps in healthcare delivery and prescribing patterns, aiming to improve policy, patient outcomes, and clinical protocols. His interdisciplinary research interests reflect his training in pharmacy, health management, and public health, empowering him to make meaningful contributions to both academic literature and healthcare practice.

Research Skills

Dr. Khaliq possesses a broad and advanced set of research skills that enhance his ability to contribute to multidisciplinary studies and clinical investigations. He is highly proficient in clinical trial management, including participant recruitment, data collection, and adverse event reporting. His expertise extends to secondary data analysis, especially in reviewing hospital records, surveillance data, and immunization outcomes. He is experienced in systematic reviews and meta-analyses, utilizing medical databases and analytical frameworks to synthesize health evidence. Dr. Khaliq also brings strong capabilities in pharmacovigilance, therapeutic drug monitoring, and drug utilization evaluations. In the realm of academic publishing, he has served as a guest editor and peer reviewer, contributing to journal special issues and maintaining scientific rigor. He is adept at grant proposal development, contributing to multiple research applications during his tenure at academic and healthcare institutions. Moreover, his familiarity with health informatics tools—such as Micromedex, MedAdvisor, and clinical guidelines—enables him to integrate real-time data with clinical decision-making. His research skills are complemented by his teaching experience and mentorship, allowing him to train future researchers and practitioners in evidence-based methods.

Awards and Honors

Dr. Asif Khaliq has garnered recognition for his dedication to public health research and pharmaceutical practice through various academic and professional achievements. He was a selected speaker at notable international forums such as the IMPACT MAKER 2020 conference in Brisbane, where he presented novel research on coexisting forms of malnutrition. His earlier work on poisoning case management was also showcased at the 4th FMIC Conference in Kabul. At the 11th International Coalition Against Typhoid Conference in Hanoi, Vietnam, Dr. Khaliq presented two critical posters on typhoid drug resistance and outbreak investigation, underscoring his commitment to infectious disease research. He has published approximately 30 peer-reviewed papers, several of which have appeared in reputable international journals. While formal individual awards may not be listed, his multiple research leadership roles, international conference engagements, and responsibilities as a guest editor reflect his strong reputation in both academic and healthcare sectors. His continuous pursuit of professional certifications, including immunization and UTI management, also highlights a dedication to clinical excellence. These accomplishments collectively underscore his potential as an award-worthy contributor to global health and pharmacy practice.

Conclusion

In conclusion, Dr. Asif Khaliq exemplifies the ideal profile of a clinical researcher who bridges academic insight with frontline healthcare delivery. His academic credentials across pharmacy, health management, and public health are complemented by his extensive experience in clinical pharmacy settings in both Pakistan and Australia. Through his research on antibiotic use, immunization safety, and medication optimization, Dr. Khaliq addresses key healthcare challenges relevant to global and regional populations. He demonstrates not only technical knowledge but also leadership in research coordination, interdisciplinary collaboration, and scientific communication. His professional ethos is defined by evidence-based practice, patient-centered care, and continual improvement. As a registered pharmacist in two countries and an active participant in international academic dialogues, Dr. Khaliq is well-positioned to further influence policy, education, and clinical standards. His consistent pursuit of professional development, publication, and mentorship reflects a commitment to excellence that aligns with the objectives of the Best Researcher Award. Recognizing his contributions would not only honor individual achievement but also highlight the critical role of pharmacist-researchers in shaping modern healthcare systems.

Publications Top Notes

1. Mission of Polio Eradication in Pakistan – A Review on Challenges and Future Recommendations

  • Year: 2025

  • Source: New Microbes and New Infections (Open Access)

2. Adherence to Complementary Feeding Indicators and Their Associations with Coexisting Forms of Malnutrition in Children Aged Between 6 to 23.9 Months of Age

  • Year: 2023

  • Source: Journal of Public Health

 

Gollapalle Lakshminarayanshastry Viswanatha | Pharmacology | Best Researcher Award

Published on by World Science Awards

Dr. Gollapalle Lakshminarayanshastry Viswanatha | Pharmacology | Best Researcher Award

Manipal College of Pharmaceutical Sciences, MAHE, Manipal, India

Dr. Gollapalle L. Viswanatha is a distinguished pharmacologist and toxicologist with over 17 years of expertise in pharmaceutical R&D, regulatory toxicology, and preclinical research. Currently serving as a Manager at ClinChoice Pvt. Ltd., Bengaluru, he has held pivotal roles in organizations like IQVIA, The Himalaya Drug Company, and Connexios Life Sciences. A prolific academic and industry contributor, Dr. Viswanatha has authored over 100 peer-reviewed articles and delivered more than 20 expert talks in global forums. As a DABT-certified and European Registered Toxicologist (ERT), his work bridges cutting-edge science with regulatory excellence. He also serves as adjunct faculty at Manipal College of Pharmaceutical Sciences, mentoring postgraduate students and contributing to academic research. His pioneering efforts in herbal drug evaluation, regulatory documentation, and systematic reviews make him a leading voice in toxicology and pharmacology. With several novel animal models to his credit, he actively influences drug discovery and translational medicine.

Professional Profile

Educational 

Dr. Viswanatha holds a PhD in Pharmaceutical Sciences (2019) from JNTU Anantapur, with a dissertation focused on indigenous medicinal plants against stroke and epilepsy. He is board-certified by the American Board of Toxicology (DABT, 2023) and recognized as a European Registered Toxicologist (ERT, 2022). He completed a PG Diploma in Statistical Quality Control and earned a Six Sigma Green Belt from the Indian Statistical Institute (ISI), Bengaluru in 2017, both with Grade ‘A’. He holds an M. Pharm in Pharmacology (2008) from RGUHS, Bengaluru, graduating with 77% and was honored as the Best Outgoing Student. Additionally, he is a GATE and GPAT qualifier. His academic foundation is marked by a multidisciplinary understanding of pharmacology, quality systems, and toxicology. Throughout his academic journey, he has demonstrated a commitment to both practical research and methodological rigor, blending statistical competence with clinical relevance in drug discovery and safety sciences.

Professional Experience

Dr. Viswanatha has a robust professional background spanning regulatory toxicology, preclinical pharmacology, and data surveillance. Currently, he leads the toxicology division at ClinChoice Pvt. Ltd. (2021–present), overseeing cosmetic ingredient safety, CTD preparation, biocompatibility risk assessments, and toxicological risk evaluations. He formerly worked at IQVIA India Pvt. Ltd. (2014–2021) as a Senior Medical Data Reviewer, specializing in clinical trial surveillance and protocol compliance for myocardial infarction studies. Prior to that, he served as a Research Associate at The Himalaya Drug Company (2010–2014), standardizing herbal drug models, and as a Scientist at Connexios Life Sciences (2008–2010), handling PK, safety pharmacology, and toxicological assessments of NCEs. His interdisciplinary approach combines GLP compliance, regulatory documentation, safety evaluations, and project leadership. With broad expertise across pharmaceuticals, nutraceuticals, and cosmetics, he has contributed to product development from discovery to regulatory submission while mentoring cross-functional teams and managing end-to-end project execution.

Awards and Honors 

Dr. Viswanatha has received numerous accolades throughout his academic and professional journey. He was honored with the prestigious Joe-Mae International Young Scientist Award by the AMS Society in Hong Kong (2016) and was a nominee for the Dr. Achari Award at IPSCON 2012 for his work on a novel pharyngitis animal model. He earned the title of Best Outgoing Student during his M. Pharm (2006–2008) and successfully qualified in GATE 2007, GPAT 2010 & 2011. His innovative contributions include the development of novel animal models for non-infectious pharyngitis and hemorrhoids. He has been invited for over 10 expert talks, delivered 5 hands-on workshops, and reviewed articles for over 35 high-impact journals, reflecting his standing as a respected thought leader. These honors underscore his commitment to translational pharmacology, scientific innovation, and academic mentorship, bridging traditional medicine with modern pharmacological practices.

Research Interests 

Dr. Viswanatha’s research interests span preclinical pharmacology, regulatory toxicology, herbal medicine, and evidence-based drug evaluation. His work focuses on stroke, epilepsy, neurodegeneration, nephroprotection, pharyngitis, and gastrointestinal and cardiovascular pharmacology, often using rodent models. He has a strong inclination toward toxicological risk assessment (TRA), biocompatibility studies, and regulatory documentation for pharmaceuticals and cosmetics. His current pursuits involve systematic reviews and meta-analyses on both clinical and preclinical data, particularly emphasizing GABAergic modulation, anti-inflammatory agents, and flavonoids like naringin. He also contributes to safety pharmacology and real-world evidence generation. Beyond therapeutic investigations, he’s deeply involved in OECD-compliant toxicology, SCCS cosmetic safety dossiers, and ISO 10993-based device safety evaluations. His dual strength in bench science and regulatory frameworks makes his research both impactful and implementation-ready, aligning traditional pharmacological principles with global safety standards.

Research Skills

Dr. Viswanatha possesses advanced skills in in vivo and in vitro pharmacological/toxicological experimentation, including GLP-compliant animal models using rats, mice, rabbits, and guinea pigs. He is proficient in conducting acute, repeated dose, and genotoxicity studies, and safety pharmacology evaluations per ICH guidelines. He excels in meta-analysis and systematic reviews using RevMan, RoB-2, G-Power, and Newcastle-Ottawa scales, alongside regulatory documentation (CTD modules 2.4 & 2.6, CPSR, ADE/PDE/OEL assessments). He has expertise in SCCS guidelines, QSAR & AOT software tools, and data analysis using GraphPad Prism, SPSS, and Minitab. He’s also skilled in toxicological literature mining using PubMed, ECHA, PubChem, and other databases. A Six Sigma Green Belt and SQC professional, his approach blends quality systems with analytical rigor. His research strengths lie in project management, protocol development, real-world evidence integration, and regulatory toxicology strategy, making him an asset across life sciences domains.

Conclusion

Dr. Viswanatha exemplifies a rare blend of rigorous experimental pharmacology and robust regulatory toxicology. His multidisciplinary education and certifications, from PhD to international toxicology credentials, underpin his leadership in both academic and industry domains. With a strong track record in innovative animal model development, systematic reviews, and regulatory documentation, he drives preclinical-to-clinical translation effectively. His prolific publication record, awards, and advisory roles highlight a distinguished career that continues to influence global life sciences.

 Publication Top Notes

  • 🧠 Clinical study on cisplatin‑induced nephrotoxicity in humans – PA Arunkumar et al. (2012)

  • 🌿 Ethnopharmacology of Lepidium sativum Linn: A review – D Manohar et al. (2012)

  • 🍃 Antioxidant & anti-inflammatory activity of Mangifera indica leaf extracts – CG Mohan et al. (2013)

  • 🍊 Naringin’s neuroprotective neurobehavioral review/meta-analysis – GL Viswanatha et al. (2017)

  • 🍎 Isolation of antidiabetic principle from Punica granatum rinds – V Jain et al. (2012)

  • 🌳 POG‑glucose inhibits 11β‑HSD‑1 & ameliorates diet-induced diabetes – CG Mohan et al. (2013)

  • 🍋 Lemongrass oil for dexamethasone-induced hyperlipidemia – VRS Kumar et al. (2011)

  • 💊 Hepatoprotective activity of Hepax polyherbal formulation – VC Devaraj et al. (2011)

  • 🌿 Antioxidant & antimutagenic activities of Terminalia arjuna bark – GL Viswanatha et al. (2013)

  • 🩸 Rat model of hemorrhoids: anti‑hemorrhoidal study – M Azeemuddin et al. (2014)

  • 💧 LC‑MS/MS quantification of flavonoids in Moringa & Raphinus – VC Devaraj et al. (2011)

  • 🧠 Animal models of chemotherapy‑induced cognitive decline – J John et al. (2021)

  • 💡 Bacopa monnieri + rivastigmine memory reversal in rats – AHM Thippeswamy et al. (2016)

  • 🍊 Hesperidin’s neuroprotective & mitochondrial benefits – GL Viswanatha et al. (2012)

  • ⚡ Anti‑epileptic activity of Punica granatum leaf extracts – GL Viswanatha et al. (2016)

  • 🌲 Anxiolytic & anticonvulsant activity of Cedrus deodara – GL Viswanatha et al. (2009)

  • 🧠 POG‑glucose alleviates ischemia/reperfusion brain injury – GL Viswanatha et al. (2013)

  • 🧪 Anti‑ulcer effect of Raphinus sativus leaves – VC Devaraj et al. (2011)

  • 🌱 Gymnema sylvestre extract improves glucose uptake – PM Kumar et al. (2016)

  • 🍇 Phytochemical standardization of Punica granatum – V Jain et al. (2011)

  • 🌸 Anti‑fertility activity of Tabernaemontana divaricata flowers – MA Mukhram et al. (2012)

  • 🧊 Anti‑urolithiatic effect of Cedrus deodara extract – N Krishnadas et al. (2010)

  • 💩 Antidiarrheal activity of Thespesia populnea bark fractions – GL Viswanatha et al. (2011)

  • 🦴 Anti‑osteoporotic effect of herbal formula NR/CAL/06 – P Srikanta et al. (2011)

  • 🌿 Antidiarrheal activity of Lepidium sativum seed extract – D Manohar et al. (2011)

  • 🧠 Acteoside from Colebrookea – anti‑epileptic effects – GL Viswanatha et al. (2016)

  • 💊 Thienotriazines: synthesis & antihistaminic activity – GL Viswanatha et al. (2012)

  • 🧠 Punica granatum extract protects against I/R brain injury – GL Viswanatha et al. (2014)

  • 🌱 Colebrookea oppositifolia root for stroke – cerebroprotective effect – GL Viswanatha et al. (2019)

  • 💥 Anticonvulsant activity of POG‑glucose from Mangifera indica – GL Viswanatha et al. (2018)

  • 💊 Mechanisms of biochanin‑A: a pharmacological review – PV Anuranjana et al. (2010)

  • 🧬 Diabetic wound healing: update – R Keni et al. (2012)

  • 🛡️ Cardioprotective preclinical systematic review on naringin – GL Viswanatha et al. (2023)

  • 🌿 Ethnopharmacology of Lepidium sativum Linn. review – M Divanji et al. (2022)

  • 🧠 Erythrina variegata bark extract: anxiolytic & anticonvulsant – G Pitchaiah et al. (2023)

 

Justine Badee | Drug Metabolism | Best Researcher Award

Published on by World Science Awards

Dr. Justine Badee | Drug Metabolism | Best Researcher Award

Scientist from Novartis, Switzerland

Dr. Justine Badée is a distinguished pharmacokinetics researcher with over eight years of experience in the pharmaceutical industry, primarily focusing on physiologically-based pharmacokinetic (PBPK) modeling. Currently serving as a Principal Scientist II at Novartis in Basel, Switzerland, she leads modeling efforts to support drug development from First-in-Human studies to regulatory submissions. Dr. Badée holds a Ph.D. in Pharmacokinetics and Drug Metabolism from the University of Manchester and has a strong foundation as a pharmacist and researcher. Her work encompasses a wide range of applications including drug-drug interactions, pediatric dosing, lactation modeling, and biopharmaceutic assessments. In addition to her scientific contributions, she has mentored Ph.D. students, driven external collaborations with international organizations such as Simcyp and the IQ Consortium, and delivered presentations at leading global conferences. Her multi-disciplinary approach and applied modeling expertise have led to significant advancements in PBPK methodologies and their regulatory application. Dr. Badée has authored and co-authored numerous scientific publications and contributed actively to the development of industry best practices in pharmacokinetics. She is recognized not only for her technical excellence but also for her leadership, mentoring, and collaborative spirit, making her a key contributor to the field of clinical pharmacology and drug metabolism.

Professional Profile

Education

Justine Badée possesses a comprehensive and rigorous academic background in pharmacokinetics and pharmaceutical sciences. She completed her Ph.D. in Pharmacokinetics and Drug Metabolism at the Centre for Applied Pharmacokinetic Research (CAPkR), University of Manchester, UK, where she focused on hepatic uptake clearance and its in vitro to in vivo translation. Her research was supported by joint funding from AstraZeneca and the UK Biotechnology and Biological Sciences Research Council. Prior to her doctoral studies, she earned a Master’s degree in Pharmacokinetics from the Faculty of Pharmacy at University René Descartes V in Paris, France. Additionally, she holds a pharmacy degree from the same institution, completing her training as a licensed pharmacist. Her academic foundation was further strengthened by a scientific high school diploma with a physics major from Saint-Erembert High School in France. Dr. Badée’s academic journey has not only equipped her with a solid theoretical and experimental knowledge base but also cultivated a robust understanding of pharmacological principles and translational research. Her diverse educational pathway—spanning pharmaceutical sciences, clinical pharmacokinetics, and drug metabolism—has played a critical role in her ability to engage in complex modeling tasks and collaborative international research efforts in drug development.

Professional Experience

Dr. Justine Badée’s professional experience reflects a dynamic and upward trajectory in the pharmaceutical and academic sectors. Since 2019, she has been a Clinical PBPK Modeler and Principal Scientist II at Novartis in Basel, where she applies PBPK modeling to a range of clinical drug development scenarios, including DDI predictions, population-specific dosing, and regulatory submissions. She also completed a three-month managerial rotation as a Project Team Manager in oncology, supporting protocol design and pharmacokinetic analysis. Her prior postdoctoral work was jointly conducted at the Center for Pharmacometrics and Systems Pharmacology, University of Florida, and at Hoffmann-La Roche, where she advanced pediatric dose selection by investigating UGT enzyme ontogeny. As a Ph.D. student at the University of Manchester, she led projects on hepatic uptake clearance and nonlinear mixed-effects modeling. Earlier in her career, she held internships at Novartis and INSERM and served as an extern pharmacist at Beaujon Hospital in Paris. Across roles, she has integrated bench research, computational modeling, and clinical applications, resulting in a comprehensive skill set. Her trajectory from laboratory-based research to high-level modeling in an industrial setting exemplifies her adaptability, technical expertise, and commitment to translating pharmacokinetic theory into practice.

Research Interests

Dr. Badée’s research interests lie at the intersection of pharmacokinetics, drug metabolism, and translational modeling. A key focus of her work is the development and application of physiologically-based pharmacokinetic (PBPK) models to optimize drug dosing, predict drug-drug interactions, and inform regulatory decisions. She is particularly interested in special populations—pediatrics, lactating women, and patients with hepatic or renal impairment—where traditional pharmacokinetic approaches often fall short. Her research extends into enzyme ontogeny, especially hepatic UGT isoforms, and how their developmental profiles affect drug metabolism across life stages. Dr. Badée is also engaged in refining in vitro methodologies to better predict in vivo drug behavior, with a focus on improving the reliability of automated glucuronidation assays. Her interest in translational research is evident through her active involvement in industry consortia and collaborative initiatives aimed at improving PBPK workflows and regulatory confidence. Furthermore, she explores innovative model-based approaches to address complex drug development challenges, such as enzyme induction and transporter-mediated drug disposition. Through these pursuits, she contributes to bridging gaps between laboratory findings, clinical implementation, and regulatory science, demonstrating a keen interest in both theoretical development and real-world application of pharmacokinetic modeling.

Research Skills

Dr. Justine Badée possesses a robust portfolio of research skills spanning pharmacokinetic modeling, laboratory techniques, and collaborative project execution. Her core technical competencies include physiologically-based pharmacokinetic (PBPK) modeling using tools such as Simcyp, GastroPlus, and PK-Sim, as well as nonlinear mixed-effect (NLME) modeling with NONMEM. She is adept at both population pharmacokinetics and PK/PD modeling, utilizing software such as WinNonlin/Phoenix, GraphPad Prism, and R. In laboratory settings, she has conducted molecular biology experiments, bioanalytical quantification using LC-MS/MS, protein assays, and hepatocyte isolation, among others. Her experience includes designing and optimizing in vitro uptake and glucuronidation assays to model hepatic metabolism accurately. Dr. Badée’s skills extend beyond the bench and computational tasks—she is also a skilled scientific communicator and collaborator. She has mentored Ph.D. students, led cross-functional teams, and actively participated in international scientific workshops and training programs. Her ability to integrate laboratory findings into advanced modeling platforms reflects her interdisciplinary expertise. Collectively, these skills position her as a valuable contributor to both the academic and industry research ecosystems, ensuring she can translate complex scientific questions into actionable insights for drug development and regulatory strategy.

Awards and Honors

Throughout her career, Dr. Justine Badée has received multiple prestigious awards and recognitions for her scientific excellence and research impact. These include the IQ Recognition Award (2021), the American College of Clinical Pharmacology (ACCP) Wayne A. Colburn Memorial Award (2018), and the ACCP Student Award. Her poster presentations have consistently garnered top honors, winning first-place awards at the Drug Metabolism Discussion Group (DMDG) and Group of Metabolism and Pharmacokinetics (GMP) meetings in 2013 and 2014. In 2023, she received a poster award at the Marbach Drug-Drug Interaction Workshop, further underscoring her contributions to advancing PBPK modeling. In addition to these accolades, she received a certificate of outstanding reviewer for the European Journal of Pharmaceutical Sciences in 2018, recognizing her critical evaluation and contribution to scientific literature. These awards reflect both the scientific rigor and practical relevance of her research. Her consistent recognition by professional bodies and conference committees highlights her leadership in modeling-based drug development and her commitment to excellence in pharmacological science. Dr. Badée’s accolades not only mark her individual achievements but also affirm her role in shaping current and future best practices in pharmacokinetic research.

Conclusion

In conclusion, Dr. Justine Badée represents a rare combination of scientific depth, practical impact, and collaborative leadership in the field of pharmacokinetics. Her contributions span the full spectrum of drug development—from mechanistic in vitro studies to sophisticated PBPK modeling and regulatory submissions. She has successfully bridged academia and industry, delivering actionable solutions to complex pharmacokinetic challenges. Her numerous peer-reviewed publications, awards, and leadership in international collaborations reflect a researcher deeply engaged in advancing the field and mentoring the next generation. With her ability to innovate, communicate, and translate science into therapeutic outcomes, Dr. Badée has established herself as a leading figure in modeling and simulation. Her work not only informs clinical and regulatory decisions but also contributes to safer and more effective drug use in vulnerable populations. As she continues to build on this strong foundation, her career promises further innovations in model-informed drug development. Dr. Badée is an ideal candidate for recognition through the Best Researcher Award, and her work exemplifies the highest standards of scientific inquiry and professional dedication.

Publications Top Notes

  • Predicting Drug Transfer into Human Milk with the Simcyp Simulator: A contribution from the ConcePTION Project
    Macente J, Nauwelaerts N, Badée J, Huang MC, Hernandes Bonan R, Van Neste M, Smits A, Allegaert K, Severino Martins F, Annaert P.
    2025

  • Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective
    Reddy MB, Cabalu TD, de Zwart L, Ramsden D, Dowty ME, Taskar KS, Badée J, Bolleddula J, Boulu L, Fu Q, Kotsuma M, Leblanc AF, Lewis G, Liang G, Parrott N, Pilla Reddy V, Prakash C, Shah K, Umehara K, Mupkherjee D, Rehmel J, Hariparsad N.
    2025

  • Generic workflow to predict medicine concentrations in human milk using physiologically-based pharmacokinetic (PBPK) modelling – A contribution from the concePTION project
    Nauwelaerts N, Macente J, Hernandes Bonan R, Huang MC, Van Neste M, Bibi D, Badée J, Martins FS, Smiths A, Allegaert K, Bouillon T, Annaert P.
    2023

  • Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective
    Hariparsad N, Ramsden D, Taskar K, Badée J, Venkatakrishnan K, Reddy MB, Cabalu T, Mukherjee D, Rehmel J, Bolleddula J, Emani Riedmaier A, Prakash C, Chanteux H, Mao J, Umehara K, Shah K, De Zwart L, Dowty M, Kotsuma M, Li M, Pilla Reddy V, McGinnity DF, Parrott N.
    2021

  • Characterization of Hepatic UDP-Glucuronosyl Transferase Enzymes Abundance – Activity Correlations and Population Variability using a Proteomics Approach and Comparison with Cytochrome P450 Enzymes
    Takahashi RH, Forrest W, Smith AD, Badée J, Qiu N, Schmidt S, Collier CA, Parrott N, Fowler S.
    2021

  • Ontogeny of Hepatic Transporters and Drug-Metabolizing Enzymes in Humans and in Nonclinical Species
    van Groen BD, Nicolaï J, Kuik AC, van Cruchten S, van Peer E, Schmidt S, de Wildt SN, Allegaert K, de Schaepdrijver L, Annaert P, Badée J.
    2021

  • Paediatric pharmacokinetics and dose predictions: a report of a satellite meeting to the 10th Juvenile Toxicity Symposium
    van Groen BD, Pilla Reddy V, Badée J, Olivares-Morales A, Johnson TN, Nicolaï J, Annaert P, Smits A, de Wildt SN, Knibbe CAJ, de Zwart L.
    2021

  • Co-expression of human hepatic uridine diphosphate glucuronosyltransferase (UGT) proteins: Implications for ontogenetic mechanisms and isoform co-regulation
    Liu Y, Badée J, Takahashi RH, Schmidt S, Parrott N, Fowler S, Mackenzie PI, Coughtrie MWH, Collier AC.
    2020

  • Use of Phenotypically Poor Metaboliser Individual Donor Human Liver Microsomes to Identify Selective Substrates of UGT2B10
    Milani N, Qiu N, Molitor B, Badée J, Cruciani G, Fowler S.
    2020

  • Characterization of the Ontogeny of Hepatic UDP-Glucuronosyl Transferase Enzymes Based on Glucuronidation Activity Measured in Human Liver Microsomes
    Badée J, Qiu N, Collier CA, Takahashi RH, Forrest W, Parrott N, Schmidt S, Fowler S.
    2019

Mohamed Abdelbaky | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Prof. Dr. Mohamed Abdelbaky | Pharmaceutical Science | Best Researcher Award

Professor-Biochemistry from Avalon Medical School, Curaçao

Dr. Mohamed Fakhry Mohamed Abdelbaky is a distinguished professor of biochemistry with a robust academic and research background spanning over two decades. He earned his PhD in Biochemistry from Glasgow Caledonian University, UK, in 2011, following his MSc and MB.B.Ch from Minya University, Egypt. Dr. Abdelbaky has held significant academic positions across various international institutions, including Avalon University School of Medicine in Curaçao, Texila American University in Guyana, and Al Maarefa University in Saudi Arabia. His roles have encompassed curriculum development, teaching, student evaluation, and administrative leadership. His research interests are diverse, focusing on molecular biology, cancer research, and pharmacological studies, with numerous publications in reputable journals. Dr. Abdelbaky’s commitment to education and research excellence is evident through his active participation in academic committees, mentorship, and continuous professional development. His contributions have significantly advanced the field of biochemistry, making him a valuable asset to the scientific community.

Professional Profile

Education

Dr. Abdelbaky’s educational journey reflects a strong foundation in medical and biochemical sciences. He obtained his Bachelor of Medicine and Surgery (MB.B.Ch) from the Faculty of Medicine, Minya University, Egypt, in 2000. Pursuing his passion for biochemistry, he completed his Master of Science (MSc) in Biochemistry at the same institution in 2006, where his thesis focused on the effects of plasma homocysteine on VEGF levels in platelets and neutrophils. To further enhance his expertise, he pursued a PhD in Biochemistry and Molecular Biology at Glasgow Caledonian University, UK, completing it in 2011. His doctoral research investigated the biological effects of the proto-oncoprotein EVI1 in normal and transformed fibroblasts. This comprehensive educational background has equipped Dr. Abdelbaky with the knowledge and skills necessary to excel in both academic and research settings, contributing significantly to the field of biochemistry.

Professional Experience

Dr. Abdelbaky’s professional career is marked by a series of progressive academic appointments and responsibilities. He began as a Teaching Assistant at Minya University, Egypt, where he was involved in designing and supervising laboratory experiments for medical students. His dedication led to his promotion to Assistant Lecturer and subsequently to Lecturer, where he continued to contribute to teaching and research activities. He expanded his international experience by serving as a Postgraduate Demonstrator at Glasgow Caledonian University, UK, where he supervised laboratory sessions and research projects for science students. Dr. Abdelbaky furthered his academic career as an Assistant Professor at Al Maarefa University in Saudi Arabia, teaching medical biochemistry and genetics to students of various health science programs. He later joined Texila American University in Guyana as an Associate Professor, where he was responsible for curriculum design and delivery of biochemistry and medical genetics courses. Currently, he holds the position of Professor at Avalon University School of Medicine in Curaçao, where he continues to contribute to curriculum development, teaching, and student mentorship. Throughout his career, Dr. Abdelbaky has demonstrated a commitment to academic excellence and leadership in biochemistry education.

Research Interests

Dr. Abdelbaky’s research interests are centered around molecular biology, cancer research, and pharmacological studies. He has a particular focus on understanding the molecular mechanisms underlying various diseases, including cancer and metabolic disorders. His research explores the roles of specific genes and proteins in disease progression and treatment responses. Dr. Abdelbaky is also interested in the development and evaluation of pharmacological agents for disease prevention and therapy. His work often involves investigating the effects of natural compounds and pharmaceuticals on cellular and molecular pathways. Through his research, Dr. Abdelbaky aims to contribute to the development of effective diagnostic and therapeutic strategies for complex diseases, ultimately improving patient outcomes.

Research Skills

Dr. Abdelbaky possesses a comprehensive set of research skills that enable him to conduct advanced studies in biochemistry and molecular biology. He is proficient in tissue culture techniques, allowing for the cultivation and maintenance of various cell lines for experimental purposes. His expertise includes the isolation of DNA, RNA, and proteins, essential for analyzing gene and protein expression. Dr. Abdelbaky is skilled in polymerase chain reaction (PCR) and reverse transcription PCR (RT-PCR), techniques crucial for amplifying and studying specific DNA and RNA sequences. He is experienced in gene knockdown methods, which are used to study gene function by reducing gene expression. Additionally, he is adept at performing agarose and polyacrylamide gel electrophoresis (PAGE) for the separation and analysis of nucleic acids and proteins. These technical skills are fundamental to his research endeavors, enabling him to investigate complex biological processes and contribute valuable insights to the field of biochemistry.

Awards and Honors

Throughout his career, Dr. Abdelbaky has received recognition for his contributions to biochemistry and medical education. He is a member of several prestigious professional societies, including the Academy of Medical Educators (AoME) in the UK, the Egyptian Medical Syndicate, and the Egyptian Society of Medical Biochemistry. His active participation in these organizations reflects his commitment to professional development and collaboration within the scientific community. Dr. Abdelbaky has also contributed to the peer-review process for scientific journals, demonstrating his expertise and dedication to maintaining high standards in research publication. His involvement in continuous medical education (CME) programs and attendance at international conferences further highlight his pursuit of knowledge and excellence in his field. These accolades and affiliations underscore Dr. Abdelbaky’s standing as a respected figure in biochemistry and medical education.

Conclusion

Dr. Mohamed Fakhry Mohamed Abdelbaky’s extensive academic background, international teaching experience, and robust research portfolio position him as a leading figure in the field of biochemistry. His dedication to education is evident through his curriculum development efforts, mentorship, and active participation in academic committees. His research contributions have advanced the understanding of molecular mechanisms in disease and informed the development of therapeutic strategies. Dr. Abdelbaky’s technical expertise and commitment to professional growth have earned him recognition within the scientific community. His multifaceted career reflects a blend of academic excellence, research innovation, and leadership, making him a valuable asset to any institution and a strong candidate for accolades such as the Best Researcher Award.

Publications Top Notes

  1. Title: Enhanced sensitivity to hydrogen peroxide-induced apoptosis in Evi1 transformed Rat1 fibroblasts due to repression of carbonic anhydrase III
    Authors: Roy P, Reavey E, Rayne M, Roy S, Abed El Baky M, Ishii Y, Bartholomew C
    Year: 2010

  2. Title: BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia
    Authors: Roy S, Jørgensen HG, Roy P, Abed El Baky M, Melo JV, Strathdee G, Holyoake TL, Bartholomew C
    Year: 2012

  3. Title: Potential impact of urocortin I on sperm count, motility and sex hormone profiles in normal adult rats
    Authors: Hany A. El Kattawy, Mahmoud A. Naga, Ahmed Shata, Mohamed A. Elbaky
    Year: 2016

  4. Title: PTEN/PI3K/VEGF signaling pathway involved in the protective effect of xanthine oxidase inhibitor febuxostat against endometrial hyperplasia in rats
    Authors: MZ Mohamed, MF Abed El Baky, OA Hassan, HH Mohammed, AM Abdel-Aziz
    Year: 2020

  5. Title: The relation between ACKR4 and CCR7 genes expression and breast cancer metastasis
    Authors: Mostafa M. Mohammed, Olfat Shaker, Maggie M. Ramzy, Shereen S. Gaber, Heba S. Kamel, Mohamed F. Abed EL Baky
    Year: 2021

  6. Title: Aprepitant exerts anti-fibrotic effect via inhibition of TGF-β/Smad3 pathway in bleomycin-induced pulmonary fibrosis in rats
    Authors: Mervat Z. Mohamed, Mohamed F. Abed El Baky, Merhan E. Ali, Heba M. Hafez
    Year: 2022

  7. Title: Mirabegron alleviates acetic acid-induced colitis in rats: role of adiponectin and GSTM1/GSH detoxification pathway
    Authors: Mervat Z. Mohamed, Mohamed F. Abed El Baky, Sahar A. Mokhemer, Heba M. Hafez
    Year: 2023

  8. Title: Cardioprotective effect of Ginger in a rat model of myocardial damage and its possible intervention in PERK-ATF4-CHOP-PUMA apoptotic pathway
    Authors: M. M. Mohammed, N. A. A. Osman, F. M. Moura, M. F. Abedelbaky
    Year: 2023

  9. Title: Vinpocetine alleviates valproic acid-induced hepatotoxicity and neurotoxicity through activation of cAMP and PI3K/AKT/CREB pathway in rats
    Authors: Heba M. Hafez, Mohamed F. Abed El Baky, Sahar A. Mokhemer, Salma M. Hassan, Mervat Z. Mohamed
    Year: Under submission (anticipated 2024 or 2025)

Khushi Quadri | Pharmacology | Best Researcher Award

Published on by World Science Awards

Ms. Khushi Quadri | Pharmacology | Best Researcher Award

Research Scholar at SGT COLLEGE OF PHARMACY, India

Khushi Quadri is a passionate and driven researcher in the field of pharmaceutics, with a strong focus on nanotechnology, drug delivery systems, and biomedical applications. She has excelled academically, achieving an impressive 88.6% in her Master’s program at SGT University, Gurugram. Khushi has contributed extensively to the scientific community through publications in reputed journals such as Elsevier and iLiver. Her research spans diverse areas, including neurological disease treatments, biosensors, and eco-friendly nanomaterials. She has presented her work at several national and international conferences, showcasing her ability to effectively communicate complex scientific ideas. Khushi’s dedication to innovation and excellence has earned her recognition in competitions and tech fests. Alongside her academic and research pursuits, she has developed skills in teamwork, communication, and adaptability, making her a well-rounded professional.

Professional Profile

Education

Khushi Quadri has a robust academic foundation in pharmacy and pharmaceutics. She is currently completing her Master’s degree in Pharmaceutics at SGT University, Gurugram (2022-2024), where she has maintained an exceptional 88.6% score. Prior to this, she earned her Bachelor’s degree in Pharmacy from B.S. Anangpuria Institute of Pharmacy, Faridabad, achieving 75.7%. Her earlier education includes a solid performance in Class XII and Class X from Kalka Public School, Alaknanda, with scores of 86.8% and 76%, respectively. This strong educational background reflects her consistency and commitment to academic excellence.

Professional Experience

Khushi has actively engaged in professional academic and research activities. Her experience includes presenting posters at multiple international and national conferences, focusing on innovative topics like eco-friendly nanoparticles, biosensors, and drug delivery systems. She has also participated in numerous workshops, gaining hands-on knowledge in areas like tablet compression, coating techniques, and spectroscopy. Through these engagements, she has honed her research and presentation skills, enabling her to effectively contribute to the scientific community.

Research Interests

Khushi’s research interests lie at the intersection of pharmaceutics, nanotechnology, and biomedical sciences. She is particularly focused on green synthesis of nanoparticles for drug delivery and therapeutic applications, including neurological diseases and cancer treatment. Her work also explores the role of inorganic nanoparticles in water purification, biosensors, and antimicrobial therapies. Her commitment to sustainable research is evident in her studies on eco-friendly materials and their environmental impact.

Research Skills

Khushi Quadri possesses a diverse skill set that complements her research activities. She is proficient in designing and optimizing green synthesis techniques for nanoparticles and evaluating their biomedical applications. Her expertise extends to spectroscopic techniques, including FTIR and UV spectroscopy, and she has a strong grasp of Microsoft Excel and Word for data analysis and documentation. Additionally, her collaborative and adaptable nature allows her to effectively work in multidisciplinary teams, contributing innovative solutions to complex research challenges.

Awards and Honors

Khushi has been recognized for her academic and research excellence through several awards and honors. Notably, she secured 3rd rank in the Synergy Tech Fest 2023 for her project on eco-friendly mosquito repellents. She has also participated in various competitive events, including national conferences and debates, reflecting her proactive engagement with the academic community. Certificates of appreciation for her achievements in CBSE board exams and employability skills further underscore her dedication to personal and professional growth.

Conclusion 🎯

Khushi Quadri has demonstrated commendable achievements in academic performance, research, and conference participation, making her a strong candidate for early-career researcher recognition. However, for a Best Researcher Award, areas like deep specialization, innovation, international collaboration, and leadership experience may need further development.

Publication Top Notes

  1. New Approaches to the Treatment of Metabolic Dysfunction-Associated Steatotic Liver with Natural Products
    • Authors: P. Yadav, K. Quadri, R. Kadian, A. Waziri, P. Agrawal, M.S. Alam
    • Journal/Source: iLIVER
    • Year: 2024
    • Citation: P. Yadav, K. Quadri, R. Kadian, A. Waziri, P. Agrawal, M.S. Alam, “New Approaches to the Treatment of Metabolic Dysfunction-Associated Steatotic Liver with Natural Products,” iLIVER, vol. 100131, 2024.
  2. A New Era of Nanotechnology Applied in Neurological Disease Treatment
    • Authors: A.S.M.S.A. Jayamanti Pandit, Charu Bharti, Surbhi Gupta, Syed Muzammil Munawar
    • Book/Source: Essential Guide to Neurodegenerative Disorders: Mechanistic, Diagnostic and Therapeutic Insights
    • Year: 2024
    • Citation: A.S.M.S.A. Jayamanti Pandit, Charu Bharti, Surbhi Gupta, Syed Muzammil Munawar, “A New Era of Nanotechnology Applied in Neurological Disease Treatment,” in Essential Guide to Neurodegenerative Disorders: Mechanistic, Diagnostic and Therapeutic Insights, 2024.
  3. Potential Role of Probiotics in Neurological Disease Treatment
    • Authors: M.S.A. Khushi Quadri, Sagar Thakur, Sushma Chaturvedi, Renu Kadian, Geeta Rawat
    • Book/Source: Essential Guide to Neurodegenerative Disorders: Mechanistic, Diagnostic and Therapeutic Insights
    • Year: 2024
    • Citation: M.S.A. Khushi Quadri, Sagar Thakur, Sushma Chaturvedi, Renu Kadian, Geeta Rawat, “Potential Role of Probiotics in Neurological Disease Treatment,” in Essential Guide to Neurodegenerative Disorders: Mechanistic, Diagnostic and Therapeutic Insights, 2024.

 

Seval Bulut | Pharmacology | Best Researcher Award

Published on by World Science Awards

Assist. Prof. Dr. Seval Bulut | Pharmacology | Best Researcher Award

Erzincan Binali Yıldırım University at Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yıldırım University, Turkey

Dr. Seval Bulut is an accomplished researcher and Assistant Professor in the Department of Pharmacology at Erzincan Binali Yıldırım University in Turkey. With an extensive background in medicine and pharmacology, her research focuses on drug safety, therapeutic interventions, and protective effects of natural extracts on organ function. Dr. Bulut’s prolific work includes 45 research articles published in leading SSCI and SCIE journals, where she has explored biochemical and histopathological mechanisms underlying drug-induced toxicity and protective pharmacological agents. Her studies span organ systems and conditions such as hepatotoxicity, renal damage, reproductive health, and ischemic syndrome, showcasing a robust interdisciplinary approach. Dr. Bulut has contributed to advancing pharmacological research with her findings on natural compounds and coenzyme Q10’s efficacy in mitigating organ dysfunction. Her academic influence extends through her roles as a physician and educator, mentoring emerging researchers in pharmacology. Dr. Bulut’s dedication to drug safety and therapeutic research has not only bolstered her professional reputation but also holds promise for improving patient care and drug efficacy in clinical settings.

Professional Profile

Education

Dr. Seval Bulut’s educational background exemplifies her dedication to the fields of medicine and pharmacology. She earned her MD from Atatürk University Faculty of Medicine in 2001, embarking on her journey as a physician committed to improving patient outcomes. Dr. Bulut later transitioned to academia, pursuing a doctoral program at Erzincan Binali Yıldırım University’s Institute of Health Sciences, Department of Medical Pharmacology. In 2024, she completed her PhD with a thesis titled “The Effect of Liv-52 on Favipiravir-Induced Hepatotoxicity in Rats: Biochemical and Histopathological Evaluation,” demonstrating her keen focus on pharmacology, particularly in drug-induced toxicity. This advanced education has equipped Dr. Bulut with a strong foundation in both clinical and research aspects of pharmacology, enabling her to investigate the biochemical mechanisms of drug interactions and develop therapeutic strategies for organ protection. Her academic journey reflects a consistent focus on integrating medical practice with pharmacological research to address real-world health challenges.

Professional Experience

Dr. Bulut’s professional experience is rooted in her dual roles as a clinician and researcher. She initially practiced medicine across various health institutions from 2001 to 2010, gaining valuable hands-on experience that provided her with a comprehensive understanding of patient care. Transitioning to a Family Physician role between 2010 and 2024, she developed a strong patient-focused perspective, which later became integral to her research approach. Currently, Dr. Bulut serves as an Assistant Professor in the Department of Pharmacology at Erzincan Binali Yıldırım University. In this academic role, she has combined her clinical insights with research expertise, conducting studies on pharmacological interventions to protect against drug-induced organ damage. Her extensive background in clinical medicine complements her current research endeavors, where she investigates the biochemical and histopathological mechanisms of pharmacological agents. This blend of professional experience positions Dr. Bulut as a knowledgeable researcher who brings both theoretical and practical insights to her field.

Research Interests

Dr. Seval Bulut’s research interests lie at the intersection of pharmacology, toxicology, and therapeutic interventions. She is particularly focused on understanding drug-induced toxicity and the protective effects of natural compounds on organ systems. Her work has centered on evaluating the biochemical and histopathological mechanisms of various pharmacological agents, including the impact of drugs such as favipiravir on liver health. Dr. Bulut’s studies also explore natural compounds like coenzyme Q10 and cinnamon extract for their potential to mitigate organ dysfunction, particularly in kidney and liver applications. Additionally, she has examined the effects of pharmaceutical compounds on reproductive health, as well as protective pharmacological strategies for conditions such as ischemic ocular syndrome. Her research contributes to improving drug safety and efficacy, providing insights that could lead to safer clinical applications and therapeutic innovations. Through her interdisciplinary research, Dr. Bulut aims to enhance the understanding of pharmacodynamics and pharmacokinetics in therapeutic contexts.

Research Skills

Dr. Seval Bulut has developed a broad set of research skills essential to her pharmacological studies. She is adept in designing and conducting in vivo experiments, specifically using animal models to assess drug efficacy and toxicity. Her skills in biochemical and histopathological analysis are evidenced in her research on drug-induced organ toxicity, where she utilizes various biochemical markers and staining techniques to evaluate cellular and tissue changes. Dr. Bulut is also proficient in data analysis and interpretation, crucial for her work in pharmacology and toxicology, where she frequently analyzes complex datasets to draw meaningful conclusions about drug interactions and therapeutic effects. Additionally, she is skilled in the ethical and methodological aspects of animal research, ensuring that her studies meet rigorous scientific standards. Her collaborative skills are reflected in her ability to work alongside other professionals, contributing to a multidisciplinary approach in her studies on pharmacological agents and natural compounds.

Awards and Honors

Dr. Seval Bulut’s academic and professional achievements have earned her recognition in the scientific community. Her prolific publication record includes 45 research articles indexed in SSCI and SCIE, which demonstrates her commitment to advancing pharmacological research. These publications span influential journals, highlighting her research’s impact and relevance in the field. Dr. Bulut’s focus on drug safety, natural therapeutics, and organ protection has led to invitations to present her findings at international congresses, further establishing her as a respected voice in pharmacology. Additionally, her progression from a practicing physician to a PhD-holder and Assistant Professor in a highly specialized research area reflects her dedication to both medical practice and academia. Although specific awards are not listed, her consistent scholarly contributions and active research agenda signal her as a promising candidate for future awards recognizing excellence in research and contributions to pharmacology. Her work holds significant implications for clinical safety and therapeutic advancements, which are critical areas of modern medical research.

Conclusion

Dr. Seval Bulut is a strong candidate for the Best Researcher Award due to her significant contributions to pharmacological research and her commitment to addressing drug safety and therapeutic efficacy. Her expertise, publication volume, and applied research focus on organ protection and biochemical evaluation highlight her as an impactful researcher. Continued emphasis on international collaboration, active conference participation, and funding pursuit could further elevate her profile and ensure sustained research advancements.

Publications Top Notes

  1. Title: Effect of ethyl acetate extract from Usnea longissima on chemotherapy-associated multiple organ dysfunction in rats
    Authors: Bingul, E., Bulut, S., Mammadov, R., Suleyman, H., Mendil, A.S.
    Journal: Biomedicine and Pharmacotherapy
    Year: 2024
    Volume: 181
    Article ID: 117636
  2. Title: The hormonal mechanism of the effects of meperidine, sertraline, tianeptine, and their combinations on reproductive functions in female rats
    Authors: Yilmaz, B.K., Suleyman, Z., Suleyman, B., Coban, T.A., Suleyman, H.
    Journal: Biomedicine and Pharmacotherapy
    Year: 2024
    Volume: 178
    Article ID: 117160
  3. Title: Lacidipine, thiamine pyrophosphate and their combination on the ocular ischemic syndrome induced by bilateral common carotid artery ligation
    Authors: Cicek, I., Somuncu, A.M., Altuner, D., Tastan, T.B., Suleyman, H.
    Journal: International Journal of Ophthalmology
    Year: 2024
    Volume: 17, Issue 5
    Pages: 815–821
  4. Title: Effects of adenosine triphosphate, Lacidipine, and Benidipine on 5-fluorouracil-induced kidney damage in rats
    Authors: Dagel, T., Altuner, D., Suleyman, B., Gulaboglu, M., Suleyman, H.
    Journal: European Review for Medical and Pharmacological Sciences
    Year: 2024
    Volume: 28, Issue 6
    Pages: 2538–2549
  5. Title: Comparative study of the protective effects of coenzyme Q10 and cinnamon extract on possible kidney damage and dysfunction of amiodarone in rats
    Authors: Ekici, O., Gul, A., Keskin, E., Gunay, M., Suleyman, H.
    Journal: Clinical and Experimental Nephrology
    Year: 2024
  6. Title: Protective effects of thiamine pyrophosphate and cinnamon against oxidative liver damage induced by an isoniazid and rifampicin combination in rats
    Authors: Yeter, B., Mammadov, R., Koc, Z., Gulaboglu, M., Suleyman, H.
    Journal: Investigacion Clinica (Venezuela)
    Year: 2024
    Volume: 65, Issue 3
    Pages: 321–334
  7. Title: Protective effect of cinnamon extract against cobalt-induced multiple organ damage in rats
    Authors: Isik, B., Suleyman, B., Mammadov, R., Coban, T.A., Suleyman, H.
    Journal: Frontiers in Pharmacology
    Year: 2024
    Volume: 15
    Article ID: 1384181
  8. Title: Role of L-, N- and T-type calcium channels in achieving maximum analgesic and minimum toxic effect of tramadol
    Authors: Yilmaz, M., Suleyman, B., Mammadov, R., Coskun, R., Suleyman, H.
    Journal: Acta Poloniae Pharmaceutica – Drug Research
    Year: 2024
    Volume: 81, Issue 1
    Pages: 135–143
  9. Title: Protective Effect of Ramipril Against Oxidant and Proinflammatory Cytokine Damage Induced by Ischemia-Reperfusion in Ovarian Tissue in Rats
    Authors: Ulug, P., Nayki, U., Mammadov, R., Coban, T.A., Suleyman, H.
    Journal: Transplantation Proceedings
    Year: 2024
    Volume: 56, Issue 1
    Pages: 215–222
  10. Title: Effect of pycnogenol on ischemia/reperfusion-induced oxidative and inflammatory damage in the ovaries of rats
    Authors: Dinc, K., Kiremitli, S., Suleyman, B., Altuner, D., Suleyman, H.
    Journal: Tropical Journal of Pharmaceutical Research
    Year: 2023
    Volume: 22, Issue 11
    Pages: 2297–2303

 

 

Ronit Satchi-Fainaro | Pharmacology | Outstanding Scientist Award

Published on by World Science Awards

Prof Dr. Ronit Satchi-Fainaro | Pharmacology | Outstanding Scientist Award

 Cancer Biology Research Center at Tel Aviv University, Israel

Ronit Satchi-Fainaro is a prominent figure in cancer research, currently serving as a Full Professor in the Department of Physiology and Pharmacology at Tel Aviv University and Director of the Cancer Biology Research Center. With a Ph.D. in polymer chemistry and extensive postdoctoral training at renowned institutions, her research focuses on cancer biology, tumor dormancy, and the development of targeted nanomedicines. Satchi-Fainaro has pioneered multi-modality polymer therapeutics that combine anti-angiogenic agents with chemotherapeutics, significantly advancing the field of cancer treatment. Her impressive publication record includes groundbreaking articles in Nature Medicine and Cancer Cell, and she has filed multiple patents for her innovative findings. Additionally, she has received numerous accolades for her contributions to science, including the Humboldt Foundation Bessel Research Prize. Satchi-Fainaro’s leadership in interdisciplinary research and commitment to translating scientific discoveries into clinical applications make her a leading voice in modern cancer therapeutics.

Professional Profile

Education

Ronit Satchi-Fainaro has an impressive educational background that laid the foundation for her distinguished career in pharmacology and cancer research. She earned her Bachelor of Pharmacy (B.Pharm.) degree in Pharmacology from The Hebrew University, Faculty of Medicine, School of Pharmacy, in June 1995. Following her undergraduate studies, she completed an internship in Industrial Pharmacy at Perio Products Ltd. in Jerusalem in March 1996. Satchi-Fainaro then pursued her Ph.D. at the University of London, specializing in polymer chemistry, biochemistry, and cancer nanomedicine. Her doctoral research, titled “PDEPT: Polymer Directed Enzyme Prodrug Therapy,” was completed in November 1999 under the supervision of Prof. Ruth Duncan. Subsequently, she expanded her expertise through postdoctoral fellowships at Tel Aviv University and Harvard Medical School, focusing on tumor biology, molecular biology, and protein delivery, further solidifying her status as a leader in the field of cancer research and nanomedicine.

 

Professional Experience

Ronit Satchi-Fainaro is a distinguished Full Professor in the Department of Physiology and Pharmacology at Tel Aviv University and serves as the Director of the Cancer Biology Research Center. With over 15 years of leadership at the university, she has spearheaded a multidisciplinary research group focused on innovative cancer therapies. Satchi-Fainaro’s expertise encompasses polymer chemistry, biochemistry, and nanomedicine, leading to the development of targeted polymer therapeutics and nano-vaccines. She has collaborated with prominent institutions, including Harvard Medical School, where she contributed to significant advances in tumor biology and angiogenesis. Her entrepreneurial spirit is evident through her co-founding of biotech companies, such as ImmuNovation, Ltd., and her active role on various scientific advisory boards. Satchi-Fainaro has garnered numerous accolades, including the Humboldt Foundation Bessel Research Prize, reflecting her substantial impact in cancer research and drug delivery systems. Her work continues to push the boundaries of personalized medicine and cancer therapeutics

Research Interests

Ronit Satchi-Fainaro’s research interests lie at the intersection of cancer biology, pharmacology, and nanomedicine. She focuses on understanding the mechanisms underlying cancer dormancy and the tumor-host interactions that facilitate metastasis. Her innovative work involves developing targeted nanomedicines that integrate anti-stromal agents with chemotherapeutics to enhance treatment efficacy while reducing toxicity. Satchi-Fainaro’s laboratory employs advanced techniques such as molecular imaging, 3D bioprinted cancer models, and personalized theranostics to investigate tumor biology and angiogenesis. She aims to identify molecular signatures that predict tumor behavior and survivorship, driving the rational design of novel therapeutic approaches. Additionally, her interdisciplinary approach combines elements of biology, chemistry, engineering, and material sciences, facilitating the development of highly selective drug delivery systems. Through her pioneering research, Satchi-Fainaro aspires to contribute to more effective cancer therapies and improve patient outcomes in the fight against cancer.

Ronit Satchi-Fainaro has received numerous prestigious awards and honors throughout her distinguished career, reflecting her significant contributions to cancer research and nanomedicine. Notable accolades include the British Council Chevening Award, the Nagai Foundation Graduate Student Award, and the Fulbright Scholarship. She was recognized as a “Person of the Year” in Medicine by Forbes Israel and included in various influential lists, such as the “50 Most Influential Women” and “40 Under 40” by prominent Israeli journals. In addition, she has received the ERC Advanced Grant, the 3D Printing Industry Award for Medical Application of the Year, and the Bessel Research Prize from the Humboldt Foundation. Her work has garnered multiple research prizes for exceptional publications at Tel Aviv University and recognition as a Fellow of the American Institute of Medical and Biological Engineers (AIMBE). These accolades highlight her impactful research and leadership in advancing innovative cancer therapies.

 

Conclusion

Ronit Satchi-Fainaro is a distinguished leader in cancer research, whose innovative work in nanomedicine has significantly advanced the understanding and treatment of cancer. With a robust academic background and over 15 years at Tel Aviv University, she has successfully led multidisciplinary research initiatives that tackle complex questions in tumor biology and drug delivery. Her pioneering development of multi-modality targeted nanomedicines has not only garnered numerous patents but also positioned her at the forefront of translational research. Satchi-Fainaro’s impressive publication record in high-impact journals, coupled with her numerous accolades—including the Humboldt Foundation Bessel Research Prize—underscores her contributions to science. As the Director of the Cancer Biology Research Center, she exemplifies a commitment to fostering collaboration and mentorship in the scientific community. Overall, her accomplishments and dedication to improving cancer therapies make her a highly deserving candidate for the Research for Outstanding Scientist Award.

 

Publication top noted
  • Title: interFLOW: maximum flow framework for the identification of factors mediating the signaling convergence of multiple receptors
    Authors: Sheinin, R., Salomon, K., Yeini, E., Sharan, R., Madi, A.
    Year: 2024
    Citations: 0
  • Title: Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy
    Authors: Longobardi, G., Moore, T.L., Conte, C., Satchi-Fainaro, R., Quaglia, F.
    Year: 2024
    Citations: 0
  • Title: Multifunctional Nanovaccine Sensitizes Breast Cancer to Immune Checkpoint Therapy
    Authors: Peres, C., Matos, A.I., Carreira, B., Satchi-Fainaro, R., Florindo, H.F.
    Year: 2024
    Citations: 2
  • Title: Combining TIGIT Blockade with MDSC Inhibition Hinders Breast Cancer Bone Metastasis by Activating Antitumor Immunity
    Authors: Monteran, L., Ershaid, N., Scharff, Y., Zhang, X.H.-F., Erez, N.
    Year: 2024
    Citations: 3
  • Title: The role of CCL2/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine
    Authors: Pozzi, S., Satchi-Fainaro, R.
    Year: 2024
    Citations: 3
  • Title: Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker
    Authors: Liubomirski, Y., Tiram, G., Scomparin, A., Shabat, D., Satchi-Fainaro, R.
    Year: 2024
    Citations: 3
  • Title: Intranasal Multiepitope PD-L1-siRNA-Based Nanovaccine: The Next-Gen COVID-19 Immunotherapy
    Authors: Acúrcio, R.C., Kleiner, R., Vaskovich-Koubi, D., Florindo, H.F., Satchi-Fainaro, R.
    Year: 2024
    Citations: 0
  • Title: Polyoxazoline-Based Nanovaccine Synergizes with Tumor-Associated Macrophage Targeting and Anti-PD-1 Immunotherapy against Solid Tumors
    Authors: Matos, A.I., Peres, C., Carreira, B., Satchi-Fainaro, R., Florindo, H.F.
    Year: 2023
    Citations: 6
  • Title: Deoxyhypusine hydroxylase: A novel therapeutic target differentially expressed in short-term vs long-term survivors of glioblastoma
    Authors: Ofek, P., Yeini, E., Arad, G., Geiger, T., Satchi-Fainaro, R.
    Year: 2023
    Citations: 4
  • Title: Development of Chitosan Particles Loaded with siRNA for Cystatin C to Control Intracellular Drug-Resistant Mycobacterium tuberculosis
    Authors: Pires, D., Mandal, M., Matos, A.I., Florindo, H.F., Anes, E.
    Year: 2023
    Citations: 6